

EPICS

Conference Coverage: EHA 2024 – Focus on NHL and CLL
Wednesday, June 26, 2024; 2.00 PM – 5.00 PM CT
Virtual Meeting

Chair: Jason Westin, MD (University of Texas MD Anderson Cancer Center)

Faculty:

- John Allan, MD (Weill Cornell Medicine)
- Joseph M. Tuscano, MD (University of California Davis Comprehensive Cancer Center)
- Mazyar Shadman, MD, MPH (Fred Hutchinson Cancer Center)
- Philippe Armand, MD, PhD (Dana-Farber Cancer Institute)
- Marc S. Hoffmann, MD (University of Kansas Cancer Center)
- Reem Karmali, MD (Northwestern University Feinberg School of Medicine)

AGENDA

Time (CT)	Topic	Presenter
2.00 PM – 2.05 PM (5 min)	Welcome and Introductions	Jason Westin, MD
2.05 PM – 2.15 PM (10 min)	<p>Advances in DLBCL/Aggressive B-Cell Lymphoma</p> <ul style="list-style-type: none"> • FEASIBILITY AND CLINICAL EFFICACY OF ATEZOLIZUMAB CONSOLIDATION IN HIGH RISK DIFFUSE LARGE B-CELL LYMPHOMA: FINAL ANALYSIS OF THE HOVON 151. Marcel Nijland. S236 • BIOMARKER-ADAPTED TREATMENT IN HIGH-RISK LARGE B-CELL LYMPHOMA: LONG-TERM FOLLOW-UP OF A NORDIC PHASE II TRIAL. Sirpa Leppä. S238 • FIRST DATA FROM SUBCUTANEOUS EPCORITAMAB+POLATUZUMAB VEDOTIN, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA-R-CHP) FOR FIRST-LINE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): EPCORE NHL-5. David Lavie. S239 • GOLCADOMIDE (GOLCA [CC-99282]), A POTENTIAL FIRST-IN-CLASS ORAL CELMOD™ AGENT, PLUS R-CHOP IN PATIENTS (PTS) WITH UNTREATED AGGRESSIVE B-CELL LYMPHOMA (A-BCL): SAFETY AND 12-MONTH EFFICACY RESULTS. Marc Hoffmann. S235 • SEVEN-DAY VEIN-TO-VEIN POINT-OF-CARE–MANUFACTURED CD19 CAR T CELLS (GLPG5101) 	Joseph M. Tuscano, MD

	<p>IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA: RESULTS FROM THE PHASE 1/2 ATALANTA-1 TRIAL. Marie José Kersten. S243</p> <ul style="list-style-type: none"> • TRANSCAR: A REAL-LIFE OUTCOME STUDY OF RELAPSED/REFRACTORY TRANSFORMED INDOLENT NON-HODGKIN LYMPHOMA IN THE CONTEXT OF CAR T-CELLS A DESCART ANALYSIS. Pierre Stephan. S241 • REAL-WORLD ASSESSMENT OF ANTI-CD19 CAR-T CELLS IN PATIENTS AGED 75 YEARS AND OLDER WITH RELAPSED OR REFRACTORY LARGE B CELL LYMPHOMA: A LYSA STUDY FROM THE DESCAR-T REGISTRY. Blandine Guffroy. S242 	
2.15 PM – 2.55 PM (40 min)	<p>Discussion</p> <ul style="list-style-type: none"> • In your opinion, what are the most impactful data in treatment of DLBCL/aggressive B-cell lymphoma presented at EHA 2024? <ul style="list-style-type: none"> – How will you incorporate these new data into your current treatment approach? • Are there any investigational agents of particular interest? What makes them interesting? • What changes do you expect in treatment sequencing in DLBCL, if any? • What remains an unmet clinical need in treatment of DLBCL/aggressive B-cell lymphoma? 	All
2.55 PM – 3.00 PM (5 min)	Key Takeaways for DLBCL/Aggressive B-Cell Lymphoma	Joseph M. Tuscano, MD
3.00 PM – 3.10 PM (10 min)	<p>Advances in Follicular Lymphoma and Mantle Cell Lymphoma</p> <p>Follicular Lymphoma</p> <ul style="list-style-type: none"> • PRIMARY ANALYSIS OF THE PHASE 2 ELM-2 STUDY: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA. Michał Taszner. S232 • MOSUNETUZUMAB DEMONSTRATES CLINICALLY MEANINGFUL OUTCOMES IN HIGH-RISK PATIENTS WITH HEAVILY PRE-TREATED R/R FL AFTER ≥3 YEARS OF FOLLOW-UP: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY. Sarit Assouline. S233 • EPCORITAMAB INDUCES DEEP RESPONSES IN RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): SAFETY AND POOLED EFFICACY DATA FROM EPCORE NHL-1 PIVOTAL AND CYCLE (C) 1 OPTIMIZATION (OPT) FL COHORTS. Umberto Vitolo. S234 <p>Mantle Cell Lymphoma</p>	Reem Karmali, MD

	<ul style="list-style-type: none"> GLOFITAMAB MONOTHERAPY IN PATIENTS WITH HEAVILY PRETREATED RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: UPDATED ANALYSIS FROM A PHASE I/II STUDY. Tycel Phillips. S231 A PROSPECTIVE ANALYSIS OF NEWLY DIAGNOSED MANTLE CELL LYMPHOMA: PREDICTORS AND SURVIVAL OF INDOLENT DISEASE. Sarah Mant. S230 	
3.10 PM – 3.35 PM (25 min)	<p>Discussion</p> <ul style="list-style-type: none"> In your opinion, what are the most impactful data in FL and MCL presented at EHA 2024? <ul style="list-style-type: none"> How will you incorporate these new data into your current treatment approach? Where do BTK inhibitors fit into the treatment algorithm? What future role do you expect for bispecific antibodies in the treatment continuum? What drives your selection of antibody-based regimens over small-molecule therapies? What remains an unmet clinical need in FL and MCL? 	All
3.35 PM – 3.40 PM (5 min)	Key Takeaways for Follicular Lymphoma and Mantle Cell Lymphoma	Reem Karmali, MD
3.40 PM – 3.45 PM (5 min)	Break	
3.45 PM – 3.55 PM (10 min)	<p>Updates in T-Cell Lymphoma</p> <ul style="list-style-type: none"> CLINICAL IMPLICATIONS OF CTDNA IN RESIDUAL DISEASE ASSESSMENT, PROGNOSIS PREDICTION, DISEASE MONITORING FOR NEWLY PERIPHERAL T-CELL LYMPHOMA PATIENTS. Jin-Hua Liang. S246 VALEMETOSTAT MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS: EFFICACY BY PRIOR LINES OF TREATMENT AND LAST TREATMENT OUTCOME FROM THE VALENTINE-PTCL01 STUDY. Pier Luigi Zinzani. S247 OUTCOMES OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR T-CELL LYMPHOMA: AN UPDATED ANALYSIS OF THE EBMT LYMPHOMA WORKING PARTY. Evgenii Shumilov. S245 	Philippe Armand, MD, PhD
3.55 PM – 4.15 PM (20 min)	<p>Discussion</p> <ul style="list-style-type: none"> In your opinion, what are the most impactful data in T-cell lymphoma presented at EHA 2024? Will any of the presented data change your practice? How? 	All

	<ul style="list-style-type: none"> • What is your assessment of novel and emerging agents in the treatment of T-cell lymphoma? • What are unmet needs in T-cell lymphoma treatment? 	
4.15 PM – 4.20 PM (5 min)	Key Takeaways for T-Cell Lymphoma	Philippe Armand, MD, PhD
4.20 PM – 4.30 PM (10 min)	<p>Evolving Therapies in CLL/SLL</p> <ul style="list-style-type: none"> • THE LANDSCAPE OF TP53 MUTATIONS AND THEIR PROGNOSTIC IMPACT IN CHRONIC LYMPHOCYTIC LEUKEMIA. Consuelo Bertossi. S101 (Plenary session) • COMBINATION OF ZANUBRUTINIB + VENETOCLAX FOR TREATMENT-NAIVE (TN) CLL/SLL WITH DEL(17P) AND/OR TP53: PRELIMINARY RESULTS FROM SEQUOIA ARM D. Paolo Ghia. S160 • CHARACTERISTICS ASSOCIATED WITH RESPONSE TO LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS (PTS) WITH R/R CLL/SLL: EXPLORATORY ANALYSES FROM TRANSCEND CLL 004. William G. Wierda. S158 • MINIMAL RESIDUAL DISEASE-GUIDED COMBINATION OF IBRUTINIB PLUS VENETOCLAX COMPARED TO FCR IN UNTREATED PATIENTS WITH CLL OF INTERMEDIATE RISK : INTERIM RESULTS FROM THE PHASE II FILO TRIAL. Anne-Sophie Michallet. S161 • COMBINED PIPTOBRUTINIB, VENETOCLAX, AND OBINUTUZUMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PHASE 2 TRIAL. Nitin Jain. S164 • 7-YEAR UPDATE ON A PHASE 2 TRIAL OF FIXED-DURATION OBINUTUZUMAB, IBRUTINIB, AND VENETOCLAX FOR CLL. Kerry Rogers. S162 • SINGLE-AGENT EPCORITAMAB LEADS TO DEEP RESPONSES IN PATIENTS (PTS) WITH RICHTER'S TRANSFORMATION (RT): PRIMARY RESULTS FROM THE EPCORE CLL-1 TRIAL. Arnon P. Kater. S163 	Mazyar Shadman, MD, MPH
4.30 PM – 4.50 PM (20 min)	<p>Discussion</p> <ul style="list-style-type: none"> • In your opinion, what are the most impactful data in CLL/SLL presented at EHA 2024? • Will any of the presented data change your practice? If so, how? • What is your view of fixed-duration vs continuous therapy in CLL? • What changes do you expect in treatment sequencing in CLL, if any? • What is your approach to choosing between different BTK inhibitors for different patient types? What do you think is the optimal treatment after BTK inhibitor failure? What is your opinion about BTK inhibitor rechallenge? 	All

- | | | |
|--|---|--|
| | <ul style="list-style-type: none">• What are unmet needs in treatment of CLL/SLL? | |
|--|---|--|

4.50 PM – 4.55 PM (5 min)	Key Takeaways for CLL/SLL	Mazyar Shadman, MD, MPH
4.55 PM – 5.00 PM (5 min)	Summary and Closing Remarks	Jason Westin, MD